PBP1502 not checked

Prestige Biopharma Limited

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
27 active
32 in total · 32 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
Main trialPhase 1
“The main purpose of the study is to demonstrate pharmacokinetic (PK) equivalence of PBP1502 to the European (EU) and American (US) Humira reference products, following a single subcutaneous (SC) dose of 40 mg in healthy volunteers.”In the company’s words, NCT05108259 on ClinicalTrials.gov
Other names
Adalimumab
Copy of
Humira (Abbvie Inc)Tested side by side with the original in NCT05108259

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials32

TrialPhaseCompletesWhat it tests
Phase 1Active, not recruiting Jun 2027 To Compare the Pharmacokinetics and Safety of PBP1502 and Humira in Healthy Subjects
Phase 4Authorised not given Prevention of postoperative endoscopic recurrence with endoscopy-driven versus systematic biological therapy: a randomized, multicentre, parallel group pragmatic non-inferiority trial in adult patients with Crohn’s disease undergoing an ileocolonic resection with ileocolonic anastomosis
Phase 3Ended not given Pilot study RCT anti-NGF Adalimumab versus placebo in fasciotomy Dupuytren contracture
Phase 3/4Authorised not given Randomized controlled multicenter study comparing efficacy and safety of adalimumab to that of mycophenolate mofetil in steroid dependent non-infectious uveitis. FOCUS: treatment FOr Corticosteroid dependent UveitiS
Phase 4Authorised not given An open-label randomized trial COmparing staNdard of care versus Treat to target with telemonitoRing and patient education in patients with ulcerative cOlitis initiating adalimumab : The CONTROL trial
Phase 4Authorised not given Comparison of Vedolizumab treatment to Adalimumab dose intensification in Crohn’s disease patients with loss of response or biomarker activity to Adalimumab on first line with therapeutic drug concentration: A randomized, multicentre, controlled VEDIAN trial.
Phase 3Authorised not given A prospective, randomized, controlled, open label, assessor-blinded, parallel-group Phase III clinical trial to evaluate the impact of tapering systemic immunosuppressive therapy in a treat-to-target approach on maintaining minimal disease activity in adult subjects with psoriatic arthritis
Phase 1/2Ended not given Investigating the safety, feasibility, and optimal dose of fluorescently labeled Adalimumab-680LT for visualizing drug targeting in Inflammatory Bowel Diseases.
Phase 4Authorised not given Evaluation of a therapeutic de-eScalation strategy based on therapeutic drug MOnitOring in chronic non-infectious uveitis Treated witH adalimumab
Phase 4Authorised not given A multi-center, open, randomized, 18-month, parallel-group, superiority study to compare the effect of proactive therapeutic drug monitoring versus standard of care with regards to maintenance of sustained disease control without flare in adults with rheumatoid arthritis treated with a subcutaneous tumor necrosis factor inhibitor
Phase 3Authorised not given Combination of baricitinib and anti-TNF vs. baricitinib alone in patients with rheumatoid arthritis: a randomized placebo-controlled phase-III trial - CRI-RA
Phase 4Ended not given PeRsonalIzed MEdicine in Rheumatoid Arthritis (PRIMERA trial): a multicenter, open-label, randomized controlled trial comparing usual care with a tailor-made approach
Phase 4Authorised not given Optimizing treatment for children and adolescents with Juvenile Idiopathic Arthritis in sustained remission: a comparison of three treatment strategies. An open randomized multicenter trial assessing two different treatment withdrawal strategies compared to continued stable treatment with methotrexate and tumor necrosis factor inhibitor in children and adolescents with juvenile idiopathic arthritis in stable remission. The MOVE-JIA trial
Phase 3Ended not given CO-THEIA (COMBINATION THERAPY WITH METHOTREXATE AND ADALIMUMAB FOR UVEITIS): EFFICACY, SAFETY AND COST-EFFECTIVENESS OF METHOTREXATE, ADALIMUMAB, OR THEIR COMBINATION IN NON INFECTIOUS NON ANTERIOR UVEITIS: A MULTICENTER, RANDOMIZED, PARALLEL 3 ARMS, ACTIVE-CONTROLLED, PHASE 3 OPEN LABEL WITH BLINDED OUTCOME ASSESSMENT STUDY.
Phase 4Authorised not given Stopping anti-TNF treatment in Crohn's and Colitis patients in remission
Phase 2Authorised not given UVB : Multicenter, randomized, prospective trial comparing the Efficacy and Safety of Adalimumab to that of Tocilizumab in severe uveitis of Behçet’s disease
Phase 2Ended not given PIMOC - Personalized targeted therapies in inflammatory complex multi organ disease
Phase 4Authorised not given Design and evaluation of an individualized biodrug tapering strategy based on biodrug dosage: the MONITORA study_STEP1
Phase 3Authorised not given Comparison of azathioprine to methotrexate in combination therapy with adalimumab in Crohn’s Disease: an open-label randomized controlled trial
Phase 4Authorised not given Toward personalized medicine to guide drug withdrawal in children with juvenile idiopathic arthritis in clinical remission: a randomized clinical trial comparing early versus late drug withdrawal combining imaging and multi-Omics.
Phase 2Authorised not given BOOSTERS - BiOlogics in FOlliculitis decalvanS : an adaptaTivE tRial reSearch
Phase 4Authorised not given A randomized, two-armed, single-blind, parallel, active controlled, and non-inferiority clinical trial to Compare Efficacy and Safety of anti TNF-alfa biosimilar molecules to the originators in children with active Juvenile Idiopathic Arthritis
Phase 4Authorised not given Control Crohn Safe with episodic adalimumab monotherapy as first line treatment study
Phase 4Authorised not given FREE-study; De-escalation of anti-TNF therapy in adolescents and young adults with IBD with tight faecal calprotectin and trough level monitoring
Phase 3/4Authorised not given RANDOMIZED CONTROLLED CLINICAL TRIAL EVALUATING METHOTREXATE OR LEFLUNOMIDE + TARGETED THERAPY VERSUS METHOTREXATE OR LEFLUNOMIDE + SULFASALAZINE + HYDROXYCHLOROQUINE IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INSUFFICIENT RESPONSE TO METHOTREXATE OR LEFLUNOMIDE (The BIO-3 trial)
Phase 3/4Authorised not given IMPACT OF ANTI-TNF, VEDOLIZUMAB AND TOFACITINIB ON AORTIC STIFFNESS, CAROTID INTIMA-MEDIA THICKNESS AND CARDIOVASCULAR RISK OF PATIENTS WITH ULCERATIVE COLITIS
Phase 1/2Authorised not given Dual wavelength fluorescence imaging using fluorescently labelled adalimumab and risankizumab for visualizing drug targeting in Inflammatory Bowel Diseases (VOYAGER)
Phase 4Authorised not given Adalimumab Treatment for Patients with Hidradenitis Suppurativa at high risk of Progressing to Severe Disease: An Unblinded Randomized, Controlled Trial
Phase 4Authorised not given Tapering optimisation with placebo-based mechanisms in rheumatoid arthritis: the TOP-RA trial
Phase 4Authorised not given Optimising Arthritis Strategies in Elderly patients (≥70 years) with rheumatoid arthritis in sustained low disease activity (the OASE study): A Prospective Target Trial Emulation Study Evaluating Tapering of Disease-Modifying Anti-Rheumatic Drugs vs. Usual Care Based on Patient Preference
Phase 4Authorised not given DISCO-RA:DIScontinuation of COncomitant disease modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis patients also using TNF inhibitors - a randomized long-term non-inferiority strategy trial
Phase 4Authorised not given Treatment strategies for juvenile idiopathic arthritis patients with sustained inactive disease: A phase 4, multicentre, randomised trial comparing maintenance versus tapered TNF alpha inhibitor monotherapy - the Treat-JIA trial
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow PBP1502

Following is part of Solo: you see every change to PBP1502 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in